We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
- Authors
Jones, S E; Schottstaedt, M W; Duncan, L A; Kirby, R L; Good, R H; Mennel, R G; George, T K; Snyder, D A; Watkins, D L; Denham, C A; Hoyes, F A; Rubin, A S
- Abstract
To determine the effects of sargramostim (recombinant human granulocyte-macrophage colony-stimulating factor [rhu GM-CSF]) on the incidence, duration, and complications of myelosuppression after moderate-dose fluorouracil, doxorubicin, cyclophosphamide (FAC) adjuvant chemotherapy in patients with node-positive breast cancer.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Vol 14, Issue 11, p2976
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.1996.14.11.2976